



Ref: Syn/CS/SE/BM/2021-22/Oct/08

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

October 20, 2021

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Press Release in respect of results for the quarter and half year ended September 30, 2021.

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled **“Syngene reports second quarter results-Revenue from operations up 17% to Rs. 6,102 Mn, PAT increased 9% to Rs. 920 Mn”**

The above-mentioned press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Company Secretary and Compliance Officer
E: priyadarshini.mahapatra@syngeneintl.com

Enclosed: Press Release along with fact sheet

Press Release

Syngene reports second quarter results
Revenue from operations up 17% to Rs. 6,102 Mn,
PAT increased 9% to Rs. 920 Mn

Bangalore, October 20, 2021, Syngene International Limited today announced its second quarter results for FY22. The Company reported quarterly revenue from operations growth of 17% year-on-year to Rs. 6,102 Mn; profit after tax for the quarter, before the exceptional item, increased by 9% year-on-year to Rs. 920 Mn.

Commenting on the results, **Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited**, said, "*The second quarter was characterized by positive performances in all divisions. In Discovery Services, we saw excellent client demand, particularly within the emerging biopharma segment, as well as further expansion of our relationships with existing clients and our long-term partners in the dedicated research centers.*

During the quarter, we continued to manufacture remdesivir for COVID-19, under a voluntary licensing agreement from Gilead.

The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across our operations. These investments play an important role in enhancing productivity, reducing the impact of human error and improving quality systems across our business.

We are pleased to have delivered a strong performance in the first half of the year. Careful management of costs, coupled with a robust business continuity plan, enabled us to continue to build capability and capacity to meet the growing requirements of our clients.

Notwithstanding the continuing uncertainty of the pandemic, we believe that we are well-positioned to deliver our guidance of mid-teens revenue growth for the full year."

Quarterly Financial Highlights (All numbers are in Indian rupees in Million except margins)

	Q2 FY22	Q2 FY21	YoY Change (%)
Revenue from Operations	6,102	5,196	17%
Revenue	6,231	5,334	17%
EBITDA	1,903	1,695	12%
EBITDA margin (%)	31	32	
PAT before exceptional item	920	841	9%
PAT Margin (%)	15	16	
PAT after exceptional item	667	841	(21%)

H1 FY22 Financial Highlights (All numbers are in Indian rupees in Million except margins)

	H1 FY22	H1 FY21	YoY Change (%)
Revenue	12,047	9,412	28%
Revenue from operations	12,299	9,703	27%
EBITDA	3,676	3,093	19%
EBITDA Margin (%)	30	32	
PAT before exceptional item	1,693	1,421	19%
PAT Margin (%)	14	15	
PAT after exceptional item	1,440	1,421	1%

During the quarter, the Company has taken an exceptional downward adjustment of Rs. 253 million (net of tax) on account of the Government's recent decision in the quarter to cap the Services Export Incentive Scheme (SEIS) for research and development services at Rs. 50 million for the Financial Year 2020. From the financial year 2016 to 2019 the Company benefited from the SEIS incentive at a rate of 5% on net foreign exchange earned. Following this precedence, the Company assumed a similar SEIS incentive would be available in Financial Year 2020 and included this in the financial results for that year. With capping of incentives at Rs 50 million, the Company has reversed the differential SEIS claim receivables. This has been presented under exceptional items in the financial results for the quarter and half year ended 30 September 2021. In the absence of notification of continuation of SEIS, the company has not accrued any such incentives from FY21 onwards. Hence, the SEIS incentive reversal during the quarter for FY2020 is not indicative of the underlying performance of the business.

Business updates

The second quarter results reflect positive performances from all divisions. In Discovery Services, there was positive demand for newer services like Protein Degradation Technology (PROTACS) and peptide synthesis, complemented by key client markets in the US and Europe beginning the process of returning to normal operations.

Development Services also experienced a positive uptick in enquiries as clients restarted activities following a lull during the pandemic due to the impact of the virus on trial viability.

In biologics manufacturing, against a backdrop of the expansion of microbial manufacturing and capacity building in mammalian manufacturing, the Company also saw its client base expand during the quarter. Manufacturing of small molecules at Mangalore remains on track to achieve USFDA approval within two years.

Key appointments

As previously announced, Alex Del Priore joined the company in July and is a member of the Executive Committee. Alex will provide strategic direction for growth of the manufacturing services business, leveraging the Company's discovery and development strengths to build an effective end-to-end offering. He is responsible for the growth of the API business from the new facility in Mangalore as well as the development of the Biologics operations.

Dr Alan Collis also joined in July as the leader of the SynVent team. SynVent is the Company's platform for integrated discovery and early development which delivers strategies built in collaboration with clients to advance novel molecules into clinical trials.

In September, Dr Sridevi Khambampaty joined the Manufacturing Services organization to lead the Biopharmaceutical Development team. Sridevi will oversee the development operations for various projects including mAbs, recombinant proteins and therapeutic virus vaccines, from early phase to commercialization. She will also drive the novel drug delivery systems of next-generation biologics.

Earnings call

Syngene will host an investor call at 2.30 pm IST on October 21, 2021 where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1279/ +91 22 7115 8180. Other toll numbers are listed in the conference call invitation which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call

will also be available until July 28, 2021 on +91 22 71945757/ +91 22 66635757, Playback ID: **63039**. We will aim to post the transcript of the conference call on the Company website within seven working days of the investor conference call.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 4700 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK and Merck KGaA. For more details, visit www.syngeneintl.com

Contact details

Investor Contact	Media Contact
Krishnan G P: +91 80 6891 9807 M: +919819992927 Fax: +91 80 2852 3423 E: krishnan.g@syngeneintl.com	Shotorupa Ghosh M: +91 8450977080 Fax: +91 80 2852 3423 E: Shotorupa.ghosh@syngeneintl.com

Disclaimer: *Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.*

SYNGENE GROUP

FACT SHEET

September - 2021

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)

BALANCE SHEET

(Rs. Million)

	30 September 2021	31 March 2021
ASSETS		
Non-current assets		
Property, plant and equipment	20,686	20,322
Capital work-in-progress	2,403	2,372
Right-of-use assets	1,022	1,121
Investment property	355	376
Other intangible assets	154	191
Financial assets		
(i) Investments	1,886	2,787
(ii) Derivative assets	840	623
(iii) Other financial assets	622	1,038
Deferred tax assets (net)	753	891
Income tax assets (net)	923	867
Other non-current assets	144	177
Total non-current assets	29,788	30,765
Current assets		
Inventories	1,655	596
Financial assets		
(i) Investments	7,367	4,233
(ii) Trade receivables	3,573	3,392
(iii) Cash and cash equivalents	1,661	3,233
(iv) Bank balances other than (iii) above	1,696	3,193
(v) Derivative assets	767	713
(vi) Other financial assets	876	1,704
Other current assets	1,190	1,003
Total current assets	18,785	18,067
Total assets	48,573	48,832
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,008	4,000
Other equity	26,069	24,214
Total equity	30,077	28,214
LIABILITIES		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	5,198	5,124
(i)(a) Lease liabilities	958	1,052
(ii) Derivative liabilities	89	224
Provisions	564	520
Other non-current liabilities	2,270	2,368
Total non-current liabilities	9,079	9,288
Current liabilities		
Financial liabilities		
(i) Borrowings	2,525	2,599
(i)(a) Lease liabilities	154	154
(ii) Trade payables	2,408	2,416
(iii) Derivative liabilities	7	18
(iv) Other financial liabilities	869	937
Provisions	534	465
Current tax liabilities (net)	132	134
Other current liabilities	2,788	4,607
Total current liabilities	9,417	11,330
Total equity and liabilities	48,573	48,832

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)

PROFIT AND LOSS STATEMENT

(Rs. Millions, except per share data)

Particulars	Q2 FY 22	Q2 FY 21	Variance
<u>INCOME</u>			
Revenue from operations	6,102	5,196	17%
Other income	129	138	-7%
Total Revenue	6,231	5,334	17%
<u>EXPENDITURE</u>			
Material and power costs	1,832	1,435	28%
Staff costs	1,846	1,612	15%
Foreign exchange (net)	(104)	(68)	53%
Other expenses	754	660	14%
Material, power, staff, forex and other expenses	4,328	3,639	
EBITDA	1,903	1,695	12%
Finance costs	12	66	-82%
Depreciation and amortisation expenses	762	687	11%
PROFIT BEFORE TAX AND EXCEPTIONAL ITEM	1,129	942	20%
Tax on above	209	101	107%
PROFIT AFTER TAX BEFORE EXCEPTIONAL ITEM	920	841	9%
Exceptional item, net of taxes	(253)	-	
NET PROFIT FOR THE PERIOD	667	841	-21%
EPS - Basic	1.64	2.12	
EPS - Diluted	1.63	2.10	

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)
PROFIT AND LOSS STATEMENT

(Rs. Millions, except per share data)

Particulars	Q2 FY 22	Q1 FY 22	Variance
<u>INCOME</u>			
Revenue from operations	6,102	5,945	3%
Other income	129	123	5%
Total Revenue	6,231	6,068	3%
<u>EXPENDITURE</u>			
Material and power costs	1,832	2,082	-12%
Staff costs	1,846	1,711	8%
Foreign exchange (net)	(104)	(154)	-32%
Other expenses	754	656	15%
Material, power, staff, forex and other expenses	4,328	4,295	
EBITDA	1,903	1,773	7%
Finance costs	12	79	-85%
Depreciation and amortisation expenses	762	747	2%
PROFIT BEFORE TAX AND EXCEPTIONAL ITEM	1,129	947	19%
Tax on above	209	174	20%
PROFIT AFTER TAX BEFORE EXCEPTIONAL ITEM	920	773	19%
Exceptional item, net of taxes	(253)	-	
NET PROFIT FOR THE PERIOD	667	773	-14%
EPS - Basic	1.64	1.91	
EPS - Diluted	1.63	1.89	

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)**PROFIT AND LOSS STATEMENT****(Rs. Millions, except per share data)**

Particulars	H1 FY 22	H1 FY 21	Variance
INCOME			
Revenue from operations	12,047	9,412	28%
Other income	252	291	-13%
Total Revenue	12,299	9,703	27%
EXPENDITURE			
Material and power costs	3,914	2,454	59%
Staff costs	3,557	3,016	18%
Foreign exchange (net)	(258)	(35)	637%
Other expenses	1,410	1,175	20%
Material, power, staff, forex and other expenses	8,623	6,610	
EBITDA	3,676	3,093	19%
Finance costs	91	140	-35%
Depreciation and amortisation expenses	1,509	1,348	12%
PROFIT BEFORE TAX AND EXCEPTIONAL ITEM	2,076	1,605	29%
Tax on above	383	184	108%
PROFIT AFTER TAX BEFORE EXCEPTIONAL ITEM	1,693	1,421	19%
Exceptional item, net of taxes	(253)	-	
NET PROFIT FOR THE PERIOD	1,440	1,421	1%
EPS - Basic	3.55	3.58	
EPS - Diluted	3.53	3.57	